CFO
IDXX icon

Callan Family Office’s Idexx Laboratories IDXX Stock Holding History

Callan Family Office’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.43M Sell
4,321
-325
-7% -$208K 0.06% 303
2025
Q4 		$3.14M Buy
4,646
+2,572
+124% +$1.75M 0.07% 259
2025
Q3 		$1.33M Sell
2,074
-412
-17% -$250K 0.04% 333
2025
Q2 		$1.33M Buy
2,486
+1,939
+354% +$927K 0.04% 344
2025
Q1 		$230K Sell
547
-49
-8% -$21.3K 0.02% 498
2024
Q4 		$246K Buy
+596
New +$261K 0.02% 543

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Callan Family Office's IDXX Position: Q1 2026 in Review

Callan Family Office reduced its Idexx Laboratories (IDXX) stake by 7% in Q1 2026, selling an estimated $208K and leaving 4,321 shares worth $2.43M. The position accounts for 0.06% of the portfolio, ranked #303.

Callan Family Office first reported a position in IDXX in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.14M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Callan Family Office held 4,321 shares of Idexx Laboratories worth $2.43M as of Q1 2026.
  • Callan Family Office sold 325 Idexx Laboratories shares in Q1 2026, an estimated $208K.
  • Idexx Laboratories made up 0.06% of Callan Family Office's portfolio in Q1 2026, its #303 holding.
  • Callan Family Office first reported a position in Idexx Laboratories in Q4 2024 and has held it in 6 quarters since.
  • Callan Family Office's Idexx Laboratories position peaked at $3.14M in Q4 2025.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.